pDONR223_PIK3CA_WT Citations (2)

Originally described in: Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, Yang X, Lubonja R, Tran N, Nguyen C, Lawrence MS, Piccioni F, Bagul M, Doench JG, Chouinard CR, Wu X, Hogstrom L, Natoli T, Tamayo P, Horn H, Corsello SM, Lage K, Root DE, Subramanian A, Golub TR, Getz G, Boehm JS, Hahn WC Cancer Discov. 2016 Jul;6(7):714-26. doi: 10.1158/2159-8290.CD-16-0160. Epub 2016 May 4. PubMed Journal

---

Articles Citing pDONR223_PIK3CA_WT

Articles
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7. PubMed
Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Pemovska T, Bigenzahn JW, Srndic I, Lercher A, Bergthaler A, Cesar-Razquin A, Kartnig F, Kornauth C, Valent P, Staber PB, Superti-Furga G. Nat Commun. 2021 Dec 14;12(1):7190. doi: 10.1038/s41467-021-27329-x. PubMed

If you have published an article using this material, please email us at to have your article added to this page.